Effects of LY3848575 Versus Placebo in Participants With Painful Distal Sensory Polyneuropathy
Completed · Phase 2 · NCT06568042
Conditions: Neuropathic Pain, Distal Sensory Polyneuropathy
At a glance
- Research payments reported, 2025
- $7.8M
- U.S. investigators named
- 22
- Sites paid
- 27
- Planned or actual enrollment
- 558
About the trial
- Sponsor
- Eli Lilly and Company
- Tested
- LY3848575 (drug), Placebo (drug)
- Dates
- Started 2024-08-22; completion 2026-04-15
- Results posted
- Not yet
The purpose of this study is to evaluate how safe and how well a treatment works compared to placebo for people with nerve pain that begins in their feet and moves up the leg to just below the knee. Participation may last up to 30 weeks including screening.
From ClinicalTrials.gov, last updated 2026-07-10. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Eli Lilly and Company reported $7.8M in research payments for this study in 2025 (44 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Matthew W. Doust, MD Pain Medicine · Scottsdale, AZ
- Hemant K. Pandey, MD Neurology · Chandler, AZ
- Perminder Bhatia, MD Neurology · Fresno, CA
- Paul K. Brownstone, M.D. Clinical Pharmacology · Boulder, CO
- Carlos Escasena, M.D. Neurology · Miami Beach, FL
- Gilbert O. Mbeo, M.D. Pain Medicine · Orlando, FL
- Kester J. Nedd, DO Neurology · Miami Lakes, FL
- Anand A. Patel, MD Pain Medicine · Ormond Beach, FL
- Shital-hiten J. Upadhyay, MD Emergency Medicine · St Petersburg, FL
- Natalie L. Clarke, MD Anesthesiology · Evans, GA
- James A. Coggi, M.D. Pediatrics · West Des Moines, IA
- Jeffrey A. Norton, M.D. Pain Medicine · Lawrence, MA
- David J. Shih, MD Nephrology (Kidney) · North Dartmouth, MA
- Timothy R. Smith, M.D. Internal Medicine · Saint Peters, MO
- Bob Hutchins Internal Medicine · Jackson, MS
- Robert F. Armstrong, MD Neurology · Asheville, NC
- Sashi K. Makam, MD Internal Medicine · New Windsor, NY
- Joel Vandersluis, M.D. Neurology · Dayton, OH
- Adeyemi T. Gbohunmi, M.D., PH.D. General Practice · Fort Worth, TX
- James C. Lai, M.D. Addiction Medicine · Houston, TX
- Jamshid Lotfi, MD Neurology · Houston, TX
- Arun Arora, M.D. Psychiatry · Bellevue, WA
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Charter Research LLC $1.2M
- Mid Hudson Medical Research PLLC $838,016
- Conquest Research LLC $720,367
- Encore Medical Research of Weston LLC $720,264
- Northwest Clinical Research Center $622,163
- Lucida Clinical Trials $517,765
- Clinical Trial Network LLC $515,878
- Mdfirst Research Chandler LLC $343,030
- Research By Design LLC $310,639
- Sky Clinical Research Network Group $302,973
- New Phase Research & Development LLC $284,259
- Integrated Clinical Trial Services Inc $267,738
- Neurology Diagnostics Inc $203,561
- Biopharma Informatic Inc $194,965
- Studymetrix Research LLC $179,170
- Alpine Clinical Research Center Inc $143,987
- Sandhill Research LLC $135,337
- Neuro PAin Medical Center Inc $114,794
- Eximia Research Acquisition Ho $73,201
- Hope Research Institute LLC $44,536
- Cedar Health Research Inc $43,479
- The Center for Clinical Research $28,794
- Elligo Health Research Inc $7,770
- $2,354
- Southern California Dermatology Inc $570
- Mdfirst Research LLC $544
- Asheville Arthritis and Osteoporosis Center $500
- Cedar Health Research $360
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.